Macropore Inc. IR-Pages
MacroPore Biosurgery, Inc. – Pre-Clinical Findings
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
MacroPore Biosurgery Pre-Clinical Findings Suggest That Adipose-Derived Cells
Have the Potential to Engraft and Differentiate Into Heart Muscle
– Results Presented at the Cardiovascular Cell and Gene Therapy Conference II –
San Diego, CA, and Cambridge, MA, April 13, 2004 – MacroPore Biosurgery, Inc.
(Frankfurt: XMP) (MACP.DE) (XMP:GR) today announced pre-clinical findings that
suggest for the first time that adipose-derived regenerative cells have the
potential to engraft injured myocardium and express markers consistent with
differentiation into cardiac myocytes. These results provide early indication
that adipose-derived regenerative cells, which include adult stem cells,
endothelial progenitor cells and other growth factor producing cells, and which
were discovered by scientists at MacroPore Biosurgery, have the potential to
repair damage associated with injured cardiac muscle following heart attack. The
findings of the study, conducted by a MacroPore Biosurgery team led by John
Fraser, Ph.D., Vice President Research & Technology for MacroPore Biosurgery,
were reported at the Cardiovascular Cell and Gene Therapy Conference II in
Cambridge, MA.
The study protocol involved injecting approximately 1.0 million regenerative
cells isolated from subcutaneous adipose tissue of Rosa26 mice into recipient
mice with injured myocardium. Control mice received saline injections.
Engraftment was demonstrated by detection of donor cells one, seven and 14 days
following injection of the regenerative cells. Donor cells were not detected in
uninjured mice or in infarcts of the control animals. At 14 days after
injection, expression of cardiac markers Myosin Heavy Chain and Troponin I was
observed on donor cells consistent with the differentiation of adipose tissue-
derived regenerative cells into cardiac myocytes.
“We are encouraged by our early findings, which are the first in a series of
detailed studies we expect to issue on the use of adipose-derived regenerative
cells for the treatment of heart disease,” said Marc H. Hedrick, M.D., Chief
Scientific Officer of MacroPore Biosurgery. “These results are consistent with
our preliminary research and with studies being performed at many other research
institutes in the U.S. and abroad, which are increasingly using adipose tissue-
derived cells for a variety of tissue repair applications.”
MacroPore Biosurgery and its collaborators have shown that adipose tissue is the
richest known source of regenerative cells. MacroPore Biosurgery believes that
therapeutically useful quantities of autologous regenerative cells can be
harvested in real-time using adipose tissue as a cell source. These studies are
funded in part through a National Institutes of Health Small Business Innovation
Research grant awarded to Dr. Fraser to study the role of adipose-derived
regenerative cells in cardiac tissue repair. The company is also conducting pre-
clinical studies at the University of California, Los Angeles and at Cedars
Sinai Medical Center. Other potential applications the company is exploring
include bone regeneration, cosmetic and reconstructive surgery and wound
healing.
Contact:
MacroPore Biosurgery, Inc.
Tom Baker
Media & U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
MacroPore Biosurgery, Inc.
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
edicto GmbH
Axel Mühlhaus/Sönke Knop
European Investor &
Press Agency
Tel.: +49 (0) 60 84 94 85-90
kontakt@edicto.de
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) (MACP.DE) (XMP: GR) is focused on the
discovery and development of regenerative medicine technologies. We are
committed to improving the practice of medicine by creating innovative products
that address spine and orthopedic bone repair and cardiovascular tissue repair.
Our surgical implants, which represent one of the latest advancements in spine
and orthopedic medicine, are manufactured by us and distributed exclusively
through Medtronic Sofamor Danek. We are conducting research and development for
an autologous, homologous-use, cell-based technology for the regeneration and
repair of damaged tissues throughout the body. We are currently targeting the
repair of cardiovascular tissues that are damaged after a myocardial infarction.
For further information please visit our web site http://www.macropore.com .
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2003 Form 10-K annual report for the year ended
December 31, 2003, which is available on our web site. MacroPore Biosurgery
assumes no responsibility to publicly release the results of any revision of
forward-looking statements to reflect events, trends or circumstances after the
date they are made.
end of message, (c)DGAP 13.04.2004
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
130830 Apr 04
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found